Grants8

Grant Information	Key Details	Eligibility & Funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) PAR-25-281 Programme: NIH Grants	Grant Purpose and Target Core Objective: To advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (perimenopause) and to identify novel targets for future mental health interventions or prevention efforts. Target Recipient Type and Size: Open to a broad range of entities, including higher education institutions, nonprofit organizations, for-profit organizations (including small businesses), and various government entities. No explicit organizational size limitations are specified. Designation: SECTOR-SPECIFIC Geographic Scope: Eligible applicants include entities within the U.S. and non-U.S. (Foreign Organizations) entities. Key Filtering Criteria: Research must focus on the menopausal transition, address mood/psychotic symptoms mechanistically, and involve human subjects. Grant Frequency and Program Context: This is a recurring R01 Research Project Grant, a re-issue of PAR-23-097, and has a companion R21 grant mechanism (PAR-25-282) for higher-risk projects or those with less preliminary data.	Funding Up to None USD Deadline Jan. 8, 2028, 10 p.m.	Details
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) PAR-25-226 Programme: National Institutes of Health (NIH)	Objective: To streamline the early-stage clinical evaluation of promising pharmacological interventions for Alzheimer's Disease (AD) and AD-related Dementias (ADRD) by bundling Phase 1 and Phase 1b/2a clinical trials. Target Recipient: Organizations and researchers engaged in biomedical, social, and behavioral research, specifically focusing on drug development for AD/ADRD. SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on healthcare, pharmaceutical development, and clinical research within neurodegenerative diseases. Geographic Scope: Worldwide, accepting applications from U.S. and non-U.S. entities (foreign organizations). Key Filtering Criteria: Clinical trial is required. Interventions must engage non-amyloid/non-tau mechanisms and address cognitive/neuropsychiatric symptoms across disease stages. Must include both Phase 1 (UG3) and Phase 1b/2a (UH3) activities. Definitive efficacy trials (Phase 3) are not supported. Grant Frequency and Program Context: This is a recurring funding opportunity (reissue of PAR-23-274) with multiple application cycles, part of the National Institute on Aging's (NIA) ongoing efforts under the National Alzheimer's Project Act (NAPA) to accelerate AD/ADRD research and treatment development.	Funding Up to None USD Deadline Oct. 19, 2026, 5 p.m.	Details
Unicorn Hub Innovation Lab Unicorn Hub Innovation Lab Programme: Polska Agencja Rozwoju Przedsiębiorczości (PARP)	The core objective is to provide comprehensive support, from the conceptual phase to building a functioning business model, for innovative ideas. Target recipients are individuals and teams of individuals. This is a SECTOR-AGNOSTIC grant, focusing on the development of modern solutions across various fields. The geographic scope is Poland, requiring applicants to reside within the country. Key filtering criteria include being an individual or a team with an innovative business idea. The program aims to support innovators, idea generators, entrepreneurs, managers, and scientists. The call for applications has officially ended, indicating it was a specific, time-limited program.	Funding Up to None PLN Deadline April 30, 2026, 10:59 p.m.	Details
Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed) PAR-23-126 Programme: National Institutes of Health (NIH), Office of Research Infrastructure Programs (ORIP)	Core Objective: To support the activities of the National Primate Research Centers (NPRCs) to facilitate the effective use of nonhuman primates (NHPs) in biomedical research aimed at understanding human biology, both in normal and diseased states. Explicit Identification of Target Recipient: This funding opportunity is limited to existing National Primate Research Centers (NPRCs), specifically those that were previously funded under PAR-17-144 or PAR-20-181. Designation: SECTOR-SPECIFIC (Biomedical Research, Primate Research). Geographic Scope: United States (as foreign institutions/components are not eligible); resources are to be available to investigators on a national basis. Key Filtering Criteria: Must be an already established NPRC that has received prior NIH P51 funding under the specified previous announcements. Grant Frequency and Program Context: This is a reissue of a previous funding opportunity (PAR-20-181), indicating a recurring program. It offers multiple application due dates annually through May 2026.	Funding Up to None USD Deadline May 25, 2026, 5 p.m.	Details
Call for Proposals (Non-Competitive) - Coastal Resilience to Climate Change 1-10494 Programme: ESA Coastal Resilience to Climate Change Initiative	The core objective of this grant is to develop innovative services that leverage space technology to enhance coastal resilience to climate change. - Target recipients: Companies (including SMEs and larger enterprises). - SECTOR-SPECIFIC: This grant is sector-specific, targeting environmental and climate change adaptation, space technology, urban planning, agriculture, tourism, insurance, and maritime sectors. - Geographic scope: Organizations must be located in specific ESA Member States and Cooperating States. Eligible countries include Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Hungary, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland, United Kingdom, Lithuania, and Slovakia. Additionally, Greece, Spain, and Canada are eligible under specific conditions. - Key filtering criteria for initial grant screening: Must utilize space technology, focus on climate change resilience in coastal regions, and be a company from an eligible country. - Grant frequency: This is a recurring opportunity within the ESA Business Applications programme. - Program context: It is part of the European Space Agency's (ESA) Coastal Resilience to Climate Change initiative.	Funding Up to None EUR Deadline Oct. 31, 2025, 11:59 p.m.	Details
Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional) PAR-24-330 Programme: National Institutes of Health (NIH)	The core objective of this grant is to support non-pharmacological interventions aimed at promoting sleep health, reducing sleep health disparities, and investigating sleep's role as a modifiable factor to lessen disparities in other health outcomes. It targets a broad range of organizations, including higher education institutions, non-profits, for-profits (including small businesses), and various government entities. This is a SECTOR-SPECIFIC grant focused on health research. The geographic scope for research impact is primarily on populations in the U.S. and its territories. Key filtering criteria for applicants include a focus on non-pharmacological interventions, addressing sleep health disparities, and the R01 grant type, with clinical trials being optional but subject to specific limitations. This is a recurring grant opportunity with multiple application deadlines until 2027.	Funding Up to None USD Deadline June 5, 2027, 5 p.m.	Details
Not specified Not specified Programme: Not specified	No specific grant information was provided for analysis. The input text describes general security features of .gov websites and a modal timeout message, not details about a funding opportunity. Grant's core objective: Not specified. Target recipient type and size: Not specified. SECTOR-AGNOSTIC (Cannot be determined due to lack of information). Geographic scope and location requirements: Not specified. Key filtering criteria: Not specified. Grant frequency and program context: Not specified.	Funding Up to None USD Deadline April 30, 2026, midnight	Details
Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access PAR-24-027 Programme: National Institutes of Health (NIH) - National Institute on Drug Abuse (NIDA)	The SECTOR-SPECIFIC grant, PAR-24-027, aims to provide investigators with access to Population Assessment of Tobacco and Health (PATH) Study biospecimens (urine, plasma, serum, genomic DNA) and related research data. This access enables research studies consistent with PATH Study objectives and tobacco regulatory science priorities. - Target recipient type: A wide range of organizations including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities. - Target size: Not explicitly limited by size. - Geographic scope: Organizations must be based in the United States. Foreign institutions are not eligible. - Key filtering criteria: Research must relate to tobacco regulatory science, and applicants must demonstrate a need for PATH Study biospecimens, with prior confirmation of biospecimen availability. - Grant frequency: Recurring with multiple application due dates until October 31, 2026. This is a reissue of a previous funding opportunity (PAR-21-044).	Funding Up to None USD Deadline Oct. 30, 2026, 10 p.m.	Details
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) PAR-25-170 Programme: National Institutes of Health (NIH)	The core objective of this grant is to support the rigorous development and validation of Digital Health Technology (DHT) derived biomarkers and clinical outcome assessments (COAs) for remote monitoring. These are intended to fill defined unmet clinical endpoint needs for interventional clinical trials across multiple diseases. Target Recipient Type and Size: Eligible organizations include a broad range of entities from Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), to various levels of Government entities and other community-based organizations. There are no explicit employee count restrictions, though small businesses are specifically noted as eligible for-profit entities. This is a SECTOR-SPECIFIC grant. Geographic Scope: Only U.S. organizations are eligible to apply. Foreign components (e.g., subcontractors, collaborators) are allowed, but the lead applicant must be a U.S. entity. Key Filtering Criteria: Focus on developing and validating existing DHTs for remote monitoring as clinical trial endpoints in three or more disease areas, with required patient/community engagement. Grant Frequency and Program Context: This is a Program Announcement (PAR-25-170) which typically implies a recurring funding opportunity, with multiple application due dates until June 2026, indicating it is active for several cycles.	Funding Up to None USD Deadline June 22, 2026, 5 p.m.	Details
Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed) PAR-25-315 Programme: National Institutes of Health (NIH)	This grant seeks to fund research that identifies how HIV-induced changes to the body's immune-metabolism affect immune responses and increase the risk of developing tuberculosis (TB) or hepatitis B virus (HBV) infections. - Target recipients are public and private nonprofit institutions, individuals, for-profit organizations, and various governmental entities. - SECTOR-SPECIFIC: Focused on biomedical research, infectious diseases, and immunometabolism. - Geographic scope: Worldwide, as non-U.S. entities are explicitly eligible. - Key filtering criteria: Research must specifically investigate HIV-induced immunometabolic alterations related to TB or HBV risk; clinical trials are strictly prohibited. - Grant frequency: This is a recurring grant opportunity with multiple application deadlines through January 2028, operating as an R01 Research Project Grant within the National Institutes of Health (NIH).	Funding Up to None USD Deadline Jan. 7, 2028, 10 p.m.	Details
Rekrutacja – Postaw na wiedzę i kompetencje Rekrutacja – Postaw na wiedzę i kompetencje Programme: European Funds for Social Development 2021-2027	The core objective of this grant is to raise the competencies of staff working for entities listed in the 'Baza Usług Rozwojowych' (Database of Development Services - BUR). This program targets entities registered in the BUR database ('Podmiot BUR') and potentially their cooperating partners, seeking to develop the skills and qualifications of their employees through external training and development services. - SECTOR-AGNOSTIC: The grant is open to entities from various sectors, as long as they are registered as a 'Podmiot BUR'. - Geographic scope: Poland. - Key filtering criteria: Applicant must be a registered 'Podmiot BUR' or a 'Podmiot współpracujący' meeting specific experience criteria; employee undergoing training must meet specific employment criteria. - Grant frequency: This is a recurring grant opportunity, with 8 recruitment rounds scheduled until July 2026. - Program context: It is part of a larger recruitment drive titled 'Raising the competence of BUR Entity staff', potentially funded under the 'European Funds for Social Development 2021-2027' program.	Funding Up to None PLN Deadline July 16, 2026, 8 a.m.	Details
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) PA-24-201 Programme: National Institutes of Health (NIH)	This grant provides emergency supplemental funding to existing National Institutes of Health (NIH) awardees. Its core objective is to support research and activities directly responding to a presidentially declared disaster, public health emergency, or other local/regional/national disaster. This funding is accessed through specific 'Emergency Notices of Special Interest (NOSIs)' published by NIH Institutes/Centers that refer to this mechanism. Target recipients are organizations already holding an active NIH grant or cooperative agreement. SECTOR-AGNOSTIC as the original research scope of the parent award can vary widely, but typically involves biomedical research, public health, or health-related fields. Geographic scope covers both U.S. and non-U.S. entities that hold an existing NIH award. Key filtering criteria: Must possess an active NIH grant and your proposed work must directly address an officially declared emergency referenced by a specific NOSI. This is a recurring mechanism, reissued from PA-20-135, and is available until April 19, 2027, but specific application opportunities depend on the release of Emergency NOSIs.	Funding Up to None USD Deadline April 19, 2027, 11:59 p.m.	Details
Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed) PAR-24-112 Programme: National Institutes of Health (NIH)	Grant's core objective: To support research that enhances understanding of the fundamental mechanisms and biomarkers of 'trained immunity' (innate immune memory), and its functional implications for immune system development, immunity to vaccines or natural infections, or allergic diseases, autoimmunity, and organ/tissue/cell transplantation rejection. Target recipient type and size: A broad range of organizations including higher education institutions, non-profits, for-profit businesses (small to large), and various governmental entities. Organizational size is not defined by employee count but by entity type. SECTOR-SPECIFIC/SECTOR-AGNOSTIC: SECTOR-SPECIFIC (Healthcare, Immunology, Infectious Diseases, Autoimmunity, Transplantation Research). Geographic scope: Organizations from the U.S. and non-U.S. (Foreign Organizations) are eligible to apply. Key filtering criteria for initial grant screening: Focus must be on basic mechanisms and biomarkers of trained immunity. Clinical trials are not allowed. Studies of adaptive immunity are non-responsive unless clearly connected to trained immunity. Projects focusing only on applications of trained immunity without novel characterizations of molecular mechanisms or biomarkers are non-responsive. Studies in non-mammalian model systems are non-responsive unless there are clear plans for translation to mammalian immunology. Applications related to HIV/AIDS are non-responsive. Grant frequency: Recurring funding opportunity with multiple annual application due dates until January 08, 2027.	Funding Up to None USD Deadline Oct. 5, 2026, 5 p.m.	Details
Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional) PAR-25-299 Programme: National Institutes of Health (NIH)	Core Objective: This grant aims to support the development and testing of multi-level and/or multi-domain intervention research to effectively reduce disparities in liver diseases and liver cancer among populations experiencing health disparities in the United States and its territories. Target Recipient Type: Primarily research institutions, non-profits, governmental agencies, and for-profit organizations capable of conducting public health and biomedical research. Target Recipient Size: Not specified, open to a wide range of organizational sizes. SECTOR-SPECIFIC: This grant is sector-specific, focusing on Healthcare, Public Health, and Biomedical Research. Geographic Scope: United States (U.S.) and its territories. Key Filtering Criteria: Focus on health disparities, intervention research, U.S. populations, and liver diseases/cancer. Clinical trials are optional. Grant Frequency: This is a recurring funding opportunity with multiple application due dates until January 2028, indicating it's part of an ongoing program.	Funding Up to None USD Deadline Nov. 5, 2027, 5 p.m.	Details
Intellectual Property Support Opportunities VLAIO IE Programme: Intellectuele eigendom steunmogelijkheden	Core objective: To provide a comprehensive overview of various financial support and advisory measures aimed at helping businesses and individuals invest in and protect intellectual property (IP) rights. Explicit identification of target recipient type and size: Enterprises (ranging from micro-enterprises to large companies), SMEs (small and medium-sized enterprises), non-profit organizations with economic activity, universities, research organizations, and natural persons. MUST state if grant is 'SECTOR-AGNOSTIC' or 'SECTOR-SPECIFIC': SECTOR-AGNOSTIC. Geographic scope and any location requirements: Primarily Belgium, especially Flanders for VLAIO-specific measures. European Union for EUIPO/EPO-related measures. Key filtering criteria for initial grant screening: Interest in intellectual property (patents, copyrights, trademarks, software, breeders' rights, data/market exclusivity), type of organization, and size (SME, micro) depending on the specific measure. Grant frequency and program context: This is an ongoing overview of multiple existing and recurring support programs and fiscal benefits related to IP.	Funding Up to None EUR Deadline Dec. 5, 2025, 10:59 p.m.	Details
NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) PAR-23-204 Programme: National Institutes of Health (NIH)	This grant, the 'NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)', aims to support organizations establishing a Coordinating Center for investigator-initiated large-scale clinical trials focused on vision disorders. The target recipients are organizations that can provide scientific and technical leadership for trial statistical and data management activities, and oversee other investigators conducting the study. This is a SECTOR-SPECIFIC grant, specifically targeting clinical research in vision. Geographic scope is broadly defined, welcoming applications from U.S. and foreign institutions. Key filtering criteria include the requirement for the proposed project to be a clinical trial, involve complex or high-risk studies, and focus on interventions for vision disorders. This is a recurring grant opportunity, indicated by its reissuance (Reissue of PAR-21-042) and multiple submission cycles.	Funding Up to None USD Deadline Jan. 25, 2026, 10 p.m.	Details
University Nuclear Leadership Program (UNLP) Scholarship and Fellowship Support Funding Opportunity UNLP S&F FOA Amendment 004 Programme: Nuclear Energy University Program	The University Nuclear Leadership Program (UNLP) Scholarship and Fellowship Support Funding Opportunity aims to provide financial assistance to undergraduate and graduate students pursuing studies in nuclear energy. - Single clear statement: This opportunity supports the education and development of the next generation of nuclear science and engineering professionals in the United States. - Target recipient type and size: Individual students (undergraduate, first-year graduate, second-year graduate) pursuing nuclear energy related studies. - Administering organizations: Academic institutions (two-year institutions, four-year institutions, community colleges, trade schools). - MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Nuclear Energy) - Geographic scope and any location requirements: United States. - Key filtering criteria: Applicant must be an eligible student (undergraduate or graduate) enrolled in a nuclear energy-related program at a US academic institution. - Grant frequency and program context: This is an ongoing opportunity within the U.S. Department of Energy's Nuclear Energy University Program (NEUP), open through October 14, 2030.	Funding Up to None USD Deadline Oct. 14, 2030, 11:59 p.m.	Details
Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) PAR-25-055 Programme: National Institutes of Health (NIH)	The PAR-25-055 grant aims to support the rigorous clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. - The core objective is to establish the clinical sensitivity and specificity of biomarker measurements within the clinical population of interest, consistent with FDA guidelines. - Target recipients include a wide range of organizations, including higher education institutions, nonprofits, for-profit organizations (both small businesses and other), and various government entities. - This grant is SECTOR-SPECIFIC, focusing exclusively on neurological and neuromuscular disorders. - Geographic scope is primarily the United States, as foreign entities are not eligible to apply directly, but foreign components (collaborators) of U.S. organizations are permitted. - Key filtering criteria: applicants must already have an identified candidate biomarker, a developed and analytically validated detection method, and a clear research/clinical need and context of use. - This is a recurring grant, reissued from PAR-24-097, indicating ongoing support for biomarker validation.	Funding Up to None USD Deadline June 22, 2026, 5 p.m.	Details
Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed) PAR-23-193 Programme: National Institutes of Health (NIH)	Provides investigators access to the NICHD's Chemical Synthesis and Optimization Facility for preclinical services. The core objective is to advance non-hormonal contraceptive and reproductive health related product development towards Investigational New Drug (IND) or Investigational Device Exemption (IDE)-enabling studies. Target recipient types are broad, including universities, nonprofits, for-profit organizations, and various government entities. The grant is SECTOR-SPECIFIC focusing on healthcare, particularly reproductive health, pharmaceuticals, and biotechnology research and development. Geographic scope is global, with eligibility for both U.S. and non-U.S. entities. Key filtering criteria for initial screening include the project's focus on preclinical development towards IND/IDE and the presence of validated targets. This is a recurring opportunity with multiple application cycles per year until April 2026, and is a reissue of a previous program.	Funding Up to None USD Deadline April 3, 2026, 5 p.m.	Details
Quality Label Humanitarian Aid - Full Procedure 43963824ESCQualityLabel1623283200000 Programme: European Solidarity Corps	The core objective of this grant is to certify organizations capable of carrying out high-quality solidarity activities in compliance with the principles of the 'European Voluntary Humanitarian Aid Corps'. Obtaining this 'Quality Label' is a precondition for participation in humanitarian aid volunteering projects. - Explicit identification of target recipient type and size: Organizations (public or private bodies) seeking to participate in humanitarian aid volunteering, specifically those applying for a 'Support role' or a 'Host role'. No specific size criteria, but allows for larger organizations with branches. - MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Humanitarian Aid Volunteering) - Geographic scope and any location requirements: Eligible countries for 'Support role' are EU Member States, Overseas Countries and Territories, and associated third countries (Iceland, Liechtenstein, Turkey, North Macedonia). 'Host role' can be in non-programme countries. - Key filtering criteria for initial grant screening: Organizations involved in or intending to be involved in humanitarian aid volunteering, seeking official certification to access related projects. - Grant frequency and program context: Applications can be submitted on a continuous basis with multiple annual cut-off dates. This is part of the broader European Solidarity Corps program.	Funding Up to None None Deadline Sept. 22, 2026, 3 p.m.	Details

Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)

PAR-25-281

Programme: NIH Grants

Grant Purpose and Target

Core Objective: To advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (perimenopause) and to identify novel targets for future mental health interventions or prevention efforts.
Target Recipient Type and Size: Open to a broad range of entities, including higher education institutions, nonprofit organizations, for-profit organizations (including small businesses), and various government entities. No explicit organizational size limitations are specified.
Designation: SECTOR-SPECIFIC
Geographic Scope: Eligible applicants include entities within the U.S. and non-U.S. (Foreign Organizations) entities.
Key Filtering Criteria: Research must focus on the menopausal transition, address mood/psychotic symptoms mechanistically, and involve human subjects.
Grant Frequency and Program Context: This is a recurring R01 Research Project Grant, a re-issue of PAR-23-097, and has a companion R21 grant mechanism (PAR-25-282) for higher-risk projects or those with less preliminary data.

Funding

Up to None USD

Deadline

Jan. 8, 2028, 10 p.m.

Details

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

PAR-25-226

Programme: National Institutes of Health (NIH)

Objective: To streamline the early-stage clinical evaluation of promising pharmacological interventions for Alzheimer's Disease (AD) and AD-related Dementias (ADRD) by bundling Phase 1 and Phase 1b/2a clinical trials.
Target Recipient: Organizations and researchers engaged in biomedical, social, and behavioral research, specifically focusing on drug development for AD/ADRD.
SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on healthcare, pharmaceutical development, and clinical research within neurodegenerative diseases.
Geographic Scope: Worldwide, accepting applications from U.S. and non-U.S. entities (foreign organizations).
Key Filtering Criteria: Clinical trial is required. Interventions must engage non-amyloid/non-tau mechanisms and address cognitive/neuropsychiatric symptoms across disease stages. Must include both Phase 1 (UG3) and Phase 1b/2a (UH3) activities. Definitive efficacy trials (Phase 3) are not supported.
Grant Frequency and Program Context: This is a recurring funding opportunity (reissue of PAR-23-274) with multiple application cycles, part of the National Institute on Aging's (NIA) ongoing efforts under the National Alzheimer's Project Act (NAPA) to accelerate AD/ADRD research and treatment development.

Funding

Up to None USD

Deadline

Oct. 19, 2026, 5 p.m.

Details

Unicorn Hub Innovation Lab

Programme: Polska Agencja Rozwoju Przedsiębiorczości (PARP)

The core objective is to provide comprehensive support, from the conceptual phase to building a functioning business model, for innovative ideas.
Target recipients are individuals and teams of individuals.
This is a SECTOR-AGNOSTIC grant, focusing on the development of modern solutions across various fields.
The geographic scope is Poland, requiring applicants to reside within the country.
Key filtering criteria include being an individual or a team with an innovative business idea. The program aims to support innovators, idea generators, entrepreneurs, managers, and scientists.
The call for applications has officially ended, indicating it was a specific, time-limited program.

Funding

Up to None PLN

Deadline

April 30, 2026, 10:59 p.m.

Details

Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed)

PAR-23-126

Programme: National Institutes of Health (NIH), Office of Research Infrastructure Programs (ORIP)

Core Objective: To support the activities of the National Primate Research Centers (NPRCs) to facilitate the effective use of nonhuman primates (NHPs) in biomedical research aimed at understanding human biology, both in normal and diseased states.
Explicit Identification of Target Recipient: This funding opportunity is limited to existing National Primate Research Centers (NPRCs), specifically those that were previously funded under PAR-17-144 or PAR-20-181.
Designation: SECTOR-SPECIFIC (Biomedical Research, Primate Research).
Geographic Scope: United States (as foreign institutions/components are not eligible); resources are to be available to investigators on a national basis.
Key Filtering Criteria: Must be an already established NPRC that has received prior NIH P51 funding under the specified previous announcements.
Grant Frequency and Program Context: This is a reissue of a previous funding opportunity (PAR-20-181), indicating a recurring program. It offers multiple application due dates annually through May 2026.

Funding

Up to None USD

Deadline

May 25, 2026, 5 p.m.

Details

Call for Proposals (Non-Competitive) - Coastal Resilience to Climate Change

1-10494

Programme: ESA Coastal Resilience to Climate Change Initiative

The core objective of this grant is to develop innovative services that leverage space technology to enhance coastal resilience to climate change. - Target recipients: Companies (including SMEs and larger enterprises). - SECTOR-SPECIFIC: This grant is sector-specific, targeting environmental and climate change adaptation, space technology, urban planning, agriculture, tourism, insurance, and maritime sectors. - Geographic scope: Organizations must be located in specific ESA Member States and Cooperating States. Eligible countries include Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Hungary, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland, United Kingdom, Lithuania, and Slovakia. Additionally, Greece, Spain, and Canada are eligible under specific conditions. - Key filtering criteria for initial grant screening: Must utilize space technology, focus on climate change resilience in coastal regions, and be a company from an eligible country. - Grant frequency: This is a recurring opportunity within the ESA Business Applications programme. - Program context: It is part of the European Space Agency's (ESA) Coastal Resilience to Climate Change initiative.

Funding

Up to None EUR

Deadline

Oct. 31, 2025, 11:59 p.m.

Details

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)

PAR-24-330

Programme: National Institutes of Health (NIH)

The core objective of this grant is to support non-pharmacological interventions aimed at promoting sleep health, reducing sleep health disparities, and investigating sleep's role as a modifiable factor to lessen disparities in other health outcomes. It targets a broad range of organizations, including higher education institutions, non-profits, for-profits (including small businesses), and various government entities. This is a SECTOR-SPECIFIC grant focused on health research. The geographic scope for research impact is primarily on populations in the U.S. and its territories. Key filtering criteria for applicants include a focus on non-pharmacological interventions, addressing sleep health disparities, and the R01 grant type, with clinical trials being optional but subject to specific limitations. This is a recurring grant opportunity with multiple application deadlines until 2027.

Funding

Up to None USD

Deadline

June 5, 2027, 5 p.m.

Details

Not specified

Programme: Not specified

No specific grant information was provided for analysis. The input text describes general security features of .gov websites and a modal timeout message, not details about a funding opportunity.

Grant's core objective: Not specified.
Target recipient type and size: Not specified.
SECTOR-AGNOSTIC (Cannot be determined due to lack of information).
Geographic scope and location requirements: Not specified.
Key filtering criteria: Not specified.
Grant frequency and program context: Not specified.

Funding

Up to None USD

Deadline

April 30, 2026, midnight

Details

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

PAR-24-027

Programme: National Institutes of Health (NIH) - National Institute on Drug Abuse (NIDA)

The SECTOR-SPECIFIC grant, PAR-24-027, aims to provide investigators with access to Population Assessment of Tobacco and Health (PATH) Study biospecimens (urine, plasma, serum, genomic DNA) and related research data. This access enables research studies consistent with PATH Study objectives and tobacco regulatory science priorities. - Target recipient type: A wide range of organizations including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities. - Target size: Not explicitly limited by size. - Geographic scope: Organizations must be based in the United States. Foreign institutions are not eligible. - Key filtering criteria: Research must relate to tobacco regulatory science, and applicants must demonstrate a need for PATH Study biospecimens, with prior confirmation of biospecimen availability. - Grant frequency: Recurring with multiple application due dates until October 31, 2026. This is a reissue of a previous funding opportunity (PAR-21-044).

Funding

Up to None USD

Deadline

Oct. 30, 2026, 10 p.m.

Details

Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)

PAR-25-170

Programme: National Institutes of Health (NIH)

The core objective of this grant is to support the rigorous development and validation of Digital Health Technology (DHT) derived biomarkers and clinical outcome assessments (COAs) for remote monitoring. These are intended to fill defined unmet clinical endpoint needs for interventional clinical trials across multiple diseases.

Target Recipient Type and Size: Eligible organizations include a broad range of entities from Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), to various levels of Government entities and other community-based organizations. There are no explicit employee count restrictions, though small businesses are specifically noted as eligible for-profit entities.
This is a SECTOR-SPECIFIC grant.
Geographic Scope: Only U.S. organizations are eligible to apply. Foreign components (e.g., subcontractors, collaborators) are allowed, but the lead applicant must be a U.S. entity.
Key Filtering Criteria: Focus on developing and validating existing DHTs for remote monitoring as clinical trial endpoints in three or more disease areas, with required patient/community engagement.
Grant Frequency and Program Context: This is a Program Announcement (PAR-25-170) which typically implies a recurring funding opportunity, with multiple application due dates until June 2026, indicating it is active for several cycles.

Funding

Up to None USD

Deadline

June 22, 2026, 5 p.m.

Details

Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)

PAR-25-315

Programme: National Institutes of Health (NIH)

This grant seeks to fund research that identifies how HIV-induced changes to the body's immune-metabolism affect immune responses and increase the risk of developing tuberculosis (TB) or hepatitis B virus (HBV) infections. - Target recipients are public and private nonprofit institutions, individuals, for-profit organizations, and various governmental entities. - SECTOR-SPECIFIC: Focused on biomedical research, infectious diseases, and immunometabolism. - Geographic scope: Worldwide, as non-U.S. entities are explicitly eligible. - Key filtering criteria: Research must specifically investigate HIV-induced immunometabolic alterations related to TB or HBV risk; clinical trials are strictly prohibited. - Grant frequency: This is a recurring grant opportunity with multiple application deadlines through January 2028, operating as an R01 Research Project Grant within the National Institutes of Health (NIH).

Funding

Up to None USD

Deadline

Jan. 7, 2028, 10 p.m.

Details

Rekrutacja – Postaw na wiedzę i kompetencje

Programme: European Funds for Social Development 2021-2027

The core objective of this grant is to raise the competencies of staff working for entities listed in the 'Baza Usług Rozwojowych' (Database of Development Services - BUR). This program targets entities registered in the BUR database ('Podmiot BUR') and potentially their cooperating partners, seeking to develop the skills and qualifications of their employees through external training and development services. - SECTOR-AGNOSTIC: The grant is open to entities from various sectors, as long as they are registered as a 'Podmiot BUR'. - Geographic scope: Poland. - Key filtering criteria: Applicant must be a registered 'Podmiot BUR' or a 'Podmiot współpracujący' meeting specific experience criteria; employee undergoing training must meet specific employment criteria. - Grant frequency: This is a recurring grant opportunity, with 8 recruitment rounds scheduled until July 2026. - Program context: It is part of a larger recruitment drive titled 'Raising the competence of BUR Entity staff', potentially funded under the 'European Funds for Social Development 2021-2027' program.

Funding

Up to None PLN

Deadline

July 16, 2026, 8 a.m.

Details

Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

PA-24-201

Programme: National Institutes of Health (NIH)

This grant provides emergency supplemental funding to existing National Institutes of Health (NIH) awardees.
Its core objective is to support research and activities directly responding to a presidentially declared disaster, public health emergency, or other local/regional/national disaster.
This funding is accessed through specific 'Emergency Notices of Special Interest (NOSIs)' published by NIH Institutes/Centers that refer to this mechanism.
Target recipients are organizations already holding an active NIH grant or cooperative agreement.
SECTOR-AGNOSTIC as the original research scope of the parent award can vary widely, but typically involves biomedical research, public health, or health-related fields.
Geographic scope covers both U.S. and non-U.S. entities that hold an existing NIH award.
Key filtering criteria: Must possess an active NIH grant and your proposed work must directly address an officially declared emergency referenced by a specific NOSI.
This is a recurring mechanism, reissued from PA-20-135, and is available until April 19, 2027, but specific application opportunities depend on the release of Emergency NOSIs.

Funding

Up to None USD

Deadline

April 19, 2027, 11:59 p.m.

Details

Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)

PAR-24-112

Programme: National Institutes of Health (NIH)

Grant's core objective: To support research that enhances understanding of the fundamental mechanisms and biomarkers of 'trained immunity' (innate immune memory), and its functional implications for immune system development, immunity to vaccines or natural infections, or allergic diseases, autoimmunity, and organ/tissue/cell transplantation rejection.
Target recipient type and size: A broad range of organizations including higher education institutions, non-profits, for-profit businesses (small to large), and various governmental entities. Organizational size is not defined by employee count but by entity type.
SECTOR-SPECIFIC/SECTOR-AGNOSTIC: SECTOR-SPECIFIC (Healthcare, Immunology, Infectious Diseases, Autoimmunity, Transplantation Research).
Geographic scope: Organizations from the U.S. and non-U.S. (Foreign Organizations) are eligible to apply.
Key filtering criteria for initial grant screening:
- Focus must be on basic mechanisms and biomarkers of trained immunity.
- Clinical trials are not allowed.
- Studies of adaptive immunity are non-responsive unless clearly connected to trained immunity.
- Projects focusing only on applications of trained immunity without novel characterizations of molecular mechanisms or biomarkers are non-responsive.
- Studies in non-mammalian model systems are non-responsive unless there are clear plans for translation to mammalian immunology.
- Applications related to HIV/AIDS are non-responsive.
Grant frequency: Recurring funding opportunity with multiple annual application due dates until January 08, 2027.

Funding

Up to None USD

Deadline

Oct. 5, 2026, 5 p.m.

Details

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)

PAR-25-299

Programme: National Institutes of Health (NIH)

Core Objective: This grant aims to support the development and testing of multi-level and/or multi-domain intervention research to effectively reduce disparities in liver diseases and liver cancer among populations experiencing health disparities in the United States and its territories.
Target Recipient Type: Primarily research institutions, non-profits, governmental agencies, and for-profit organizations capable of conducting public health and biomedical research.
Target Recipient Size: Not specified, open to a wide range of organizational sizes.
SECTOR-SPECIFIC: This grant is sector-specific, focusing on Healthcare, Public Health, and Biomedical Research.
Geographic Scope: United States (U.S.) and its territories.
Key Filtering Criteria: Focus on health disparities, intervention research, U.S. populations, and liver diseases/cancer. Clinical trials are optional.
Grant Frequency: This is a recurring funding opportunity with multiple application due dates until January 2028, indicating it's part of an ongoing program.

Funding

Up to None USD

Deadline

Nov. 5, 2027, 5 p.m.

Details

Intellectual Property Support Opportunities

VLAIO IE

Programme: Intellectuele eigendom steunmogelijkheden

Core objective: To provide a comprehensive overview of various financial support and advisory measures aimed at helping businesses and individuals invest in and protect intellectual property (IP) rights.
Explicit identification of target recipient type and size: Enterprises (ranging from micro-enterprises to large companies), SMEs (small and medium-sized enterprises), non-profit organizations with economic activity, universities, research organizations, and natural persons.
MUST state if grant is 'SECTOR-AGNOSTIC' or 'SECTOR-SPECIFIC': SECTOR-AGNOSTIC.
Geographic scope and any location requirements: Primarily Belgium, especially Flanders for VLAIO-specific measures. European Union for EUIPO/EPO-related measures.
Key filtering criteria for initial grant screening: Interest in intellectual property (patents, copyrights, trademarks, software, breeders' rights, data/market exclusivity), type of organization, and size (SME, micro) depending on the specific measure.
Grant frequency and program context: This is an ongoing overview of multiple existing and recurring support programs and fiscal benefits related to IP.

Funding

Up to None EUR

Deadline

Dec. 5, 2025, 10:59 p.m.

Details

NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)

PAR-23-204

Programme: National Institutes of Health (NIH)

This grant, the 'NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)', aims to support organizations establishing a Coordinating Center for investigator-initiated large-scale clinical trials focused on vision disorders.
The target recipients are organizations that can provide scientific and technical leadership for trial statistical and data management activities, and oversee other investigators conducting the study.
This is a SECTOR-SPECIFIC grant, specifically targeting clinical research in vision.
Geographic scope is broadly defined, welcoming applications from U.S. and foreign institutions.
Key filtering criteria include the requirement for the proposed project to be a clinical trial, involve complex or high-risk studies, and focus on interventions for vision disorders.
This is a recurring grant opportunity, indicated by its reissuance (Reissue of PAR-21-042) and multiple submission cycles.

Funding

Up to None USD

Deadline

Jan. 25, 2026, 10 p.m.

Details

University Nuclear Leadership Program (UNLP) Scholarship and Fellowship Support Funding Opportunity

UNLP S&F FOA Amendment 004

Programme: Nuclear Energy University Program

The University Nuclear Leadership Program (UNLP) Scholarship and Fellowship Support Funding Opportunity aims to provide financial assistance to undergraduate and graduate students pursuing studies in nuclear energy. - Single clear statement: This opportunity supports the education and development of the next generation of nuclear science and engineering professionals in the United States. - Target recipient type and size: Individual students (undergraduate, first-year graduate, second-year graduate) pursuing nuclear energy related studies. - Administering organizations: Academic institutions (two-year institutions, four-year institutions, community colleges, trade schools). - MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Nuclear Energy) - Geographic scope and any location requirements: United States. - Key filtering criteria: Applicant must be an eligible student (undergraduate or graduate) enrolled in a nuclear energy-related program at a US academic institution. - Grant frequency and program context: This is an ongoing opportunity within the U.S. Department of Energy's Nuclear Energy University Program (NEUP), open through October 14, 2030.

Funding

Up to None USD

Deadline

Oct. 14, 2030, 11:59 p.m.

Details

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

PAR-25-055

Programme: National Institutes of Health (NIH)

The PAR-25-055 grant aims to support the rigorous clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. - The core objective is to establish the clinical sensitivity and specificity of biomarker measurements within the clinical population of interest, consistent with FDA guidelines. - Target recipients include a wide range of organizations, including higher education institutions, nonprofits, for-profit organizations (both small businesses and other), and various government entities. - This grant is SECTOR-SPECIFIC, focusing exclusively on neurological and neuromuscular disorders. - Geographic scope is primarily the United States, as foreign entities are not eligible to apply directly, but foreign components (collaborators) of U.S. organizations are permitted. - Key filtering criteria: applicants must already have an identified candidate biomarker, a developed and analytically validated detection method, and a clear research/clinical need and context of use. - This is a recurring grant, reissued from PAR-24-097, indicating ongoing support for biomarker validation.

Funding

Up to None USD

Deadline

June 22, 2026, 5 p.m.

Details

Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)

PAR-23-193

Programme: National Institutes of Health (NIH)

Provides investigators access to the NICHD's Chemical Synthesis and Optimization Facility for preclinical services.
The core objective is to advance non-hormonal contraceptive and reproductive health related product development towards Investigational New Drug (IND) or Investigational Device Exemption (IDE)-enabling studies.
Target recipient types are broad, including universities, nonprofits, for-profit organizations, and various government entities.
The grant is SECTOR-SPECIFIC focusing on healthcare, particularly reproductive health, pharmaceuticals, and biotechnology research and development.
Geographic scope is global, with eligibility for both U.S. and non-U.S. entities.
Key filtering criteria for initial screening include the project's focus on preclinical development towards IND/IDE and the presence of validated targets.
This is a recurring opportunity with multiple application cycles per year until April 2026, and is a reissue of a previous program.

Funding

Up to None USD

Deadline

April 3, 2026, 5 p.m.

Details

Quality Label Humanitarian Aid - Full Procedure

43963824ESCQualityLabel1623283200000

Programme: European Solidarity Corps

The core objective of this grant is to certify organizations capable of carrying out high-quality solidarity activities in compliance with the principles of the 'European Voluntary Humanitarian Aid Corps'. Obtaining this 'Quality Label' is a precondition for participation in humanitarian aid volunteering projects. - Explicit identification of target recipient type and size: Organizations (public or private bodies) seeking to participate in humanitarian aid volunteering, specifically those applying for a 'Support role' or a 'Host role'. No specific size criteria, but allows for larger organizations with branches. - MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Humanitarian Aid Volunteering) - Geographic scope and any location requirements: Eligible countries for 'Support role' are EU Member States, Overseas Countries and Territories, and associated third countries (Iceland, Liechtenstein, Turkey, North Macedonia). 'Host role' can be in non-programme countries. - Key filtering criteria for initial grant screening: Organizations involved in or intending to be involved in humanitarian aid volunteering, seeking official certification to access related projects. - Grant frequency and program context: Applications can be submitted on a continuous basis with multiple annual cut-off dates. This is part of the broader European Solidarity Corps program.

Funding

Up to None None

Deadline

Sept. 22, 2026, 3 p.m.

Details

You can filter by below criteria

Grants